Stock Price Quote

KILITCH DRUGS (INDIA) LTD.

NSE : KILITCHBSE : 524500ISIN CODE : INE729D01010Industry : Pharmaceuticals & DrugsHouse : Private
BSE470.40-0.6 (-0.13 %)
PREV CLOSE ( ) 471.00
OPEN PRICE ( ) 475.10
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 32449
TODAY'S LOW / HIGH ( )464.00 484.60
52 WK LOW / HIGH ( )271.3 486
NSE471.750.45 (+0.1 %)
PREV CLOSE( ) 471.30
OPEN PRICE ( ) 475.50
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 471.75 (472)
VOLUME 141397
TODAY'S LOW / HIGH( ) 462.75 483.35
52 WK LOW / HIGH ( )299.95 486
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1992
Management Info
- Chairman Mukund P Mehta - Managing Director
Registered Office

Address C 301/2 M I D C,T T C Industrial Area,Pawane Village,
Navi Mumbai,
Maharashtra-400705

Phone 022-62996300

Email info@kilitch.com

Website www.kilitch.com

Registrars Details
MUFG Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

04Feb Kilitch Drugs (India) informs about pr
Kilitch Drugs (India) has informed that it enclosed its Press Release re..
22Jan Kilitch Drugs makes additional investm
Kilitch Drugs (India) has made additional investment of $2,00,000 to acq..
22Jan Kilitch Drugs surges on making additio
Kilitch Drugs (India) is currently trading at Rs. 339.20, up by 2.20 poi..
22Oct Kilitch Drugs (India) informs about lo
Kilitch Drugs (India has informed that the Company has received intimati..
21Sep Kilitch Drugs (India) informs about lo
Kilitch Drugs (India) has informed that it enclosed intimation of Issue..

Financials

in Millions
QTR Mar 25 ANNUAL 25
Net Profit113.73311.57
Gross Profit 149.98 406.9
Operating Profit 162.3445.53
Net Sales 563.041815.87

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Glaxosmithkline Phar (BSE)
peergroup  2984.45 (7.07%)
M.Cap ( in Cr)50770.99
Caplin Point Lab (BSE)
peergroup  2250.95 (5.75%)
M.Cap ( in Cr)16973.41
Alkem Laboratories (BSE)
peergroup  5379.00 (2.25%)
M.Cap ( in Cr)64290.10
Divi's Lab (BSE)
peergroup  6558.00 (1.66%)
M.Cap ( in Cr)174146.06
Astrazeneca Pharma I (BSE)
peergroup  7999.50 (0.99%)
M.Cap ( in Cr)20067.88

Shareholding Pattern

PROMOTERS 69.23%
NON-INSTITUTION 30.77%
FI/BANKS/INSURANCE 0%
MUTUAL FUNDS/UTI 0%
GOVERNMENT 0%
FII 0%

About Kilitch Drugs (India) Ltd.

Kilitch Drugs (India) Ltd. was incorporated in the year 1992. Its today's share price is 470.4. Its current market capitalisation stands at Rs 757.48 Cr. In the latest quarter, company has reported Gross Sales of Rs. 1315.99 Cr and Total Income of Rs.1377.88 Cr. The company's management includes Pushpa Nyoupane, V S Rajan, Vasudev Krishna Murti, Mira Mehta, Bhavin M Mehta, Mukund P Mehta.

It is listed on the BSE with a BSE Code of 524500 , NSE with an NSE Symbol of KILITCH and ISIN of INE729D01010. It's Registered office is at C 301/2 M I D C,T T C Industrial Area,Pawane VillageNavi Mumbai-400705, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are AM Ghelani & Co, RNR Iyer & Co, Suryaprakash Maurya & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.